Acquisition History / BioMarin Pharmaceutical Inc. / Amicus Therapeutics, Inc.
BioMarin Pharmaceutical Inc. Acquires Amicus Therapeutics, Inc.
Announced December 19, 2025 — $4.80B
What happened
Amicus Therapeutics markets Galafold for Fabry disease and Pombiliti plus Opfolda for Pompe disease. BioMarin agreed on December 19, 2025 to acquire it for $14.50 per share in an all-cash transaction with a total equity value of about $4.8B.
- Acquirer
- BioMarin Pharmaceutical Inc.
- Target
- Amicus Therapeutics, Inc.
- Announced
- December 19, 2025
- Price
- $4.80B
- Industry
- Rare disease pharmaceuticals
- Buyer type
- Strategic acquirer
- Status
- Announced, not yet closed
By the numbers
Frequently Asked Questions About This Acquisition
When did BioMarin Pharmaceutical Inc. acquire Amicus Therapeutics, Inc.?
BioMarin Pharmaceutical Inc. acquired Amicus Therapeutics, Inc. on December 19, 2025. This was BioMarin Pharmaceutical Inc.'s 2nd publicly tracked acquisition out of 2 we have on record.
How much did BioMarin Pharmaceutical Inc. pay for Amicus Therapeutics, Inc.?
BioMarin Pharmaceutical Inc. paid $4.80B for Amicus Therapeutics, Inc..
What does Amicus Therapeutics, Inc. do?
Amicus Therapeutics markets Galafold for Fabry disease and Pombiliti plus Opfolda for Pompe disease. BioMarin agreed on December 19, 2025 to acquire it for $14.50 per share in an all-cash transaction with a total equity value of about $4.8B.
What other Rare disease pharmaceuticals companies has BioMarin Pharmaceutical Inc. acquired?
Amicus Therapeutics, Inc. is BioMarin Pharmaceutical Inc.'s only publicly tracked acquisition in Rare disease pharmaceuticals so far.
More BioMarin Pharmaceutical Inc. acquisitions
Inozyme Pharma, Inc.
$270M · 2025